ZURA vs OPTU Comparison

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

Optimum's assets were brought together when Altice Europe acquired US cable companies Suddenlink in 2015 and Cablevision in 2016. The Suddenlink business, which management calls the "West," provides television, internet access, and phone services to roughly 4.5 million US homes and businesses located primarily in smaller markets, with major clusters in Texas, West Virginia, Idaho, Arizona, and Louisiana. The Cablevision portion, dubbed the "East," provides comparable services to about 5.5 million homes and businesses in the New York City metro area. Both regions now operate under the Optimum brand name. Altice Europe spun off Optimum, which includes both the Suddenlink and Cablevision operations, to shareholders in 2018.